AccurKardia vs HeartSciences (2026)
Both work on ECGs, and they sell different layers. AccurKardia sells its own cleared interpretation: AccurECG analyzes ambulatory recordings beat by beat, detects ectopic beats and interprets 13 rhythm classes including atrial fibrillation and ventricular tachycardia, and it accepts recordings from other makers' patches and Holter monitors. It holds two FDA 510(k) clearances. HeartSciences sells the workflow around resting ECGs. MyoVista Insights ingests 12 lead ECGs from more than 30 device makers for review, reporting and sign off, and since June 2026 its algorithm marketplace shows third party AI results in that workflow, starting with Bunkerhill Health's cleared model for reduced ejection fraction. HeartSciences' own algorithms are still in development. Choose AccurKardia for cleared AI reading of monitoring data; choose HeartSciences to manage a hospital's resting ECGs, with AI from partners for now.
- Automated beat by beat interpretation of ambulatory ECG recordings across 13 rhythm classes.
- Two FDA 510(k) clearances, the latest for version 2.0 in December 2025.
- Recordings accepted from other makers' patches and Holter monitors without device specific tuning.
- A cloud platform for managing resting 12 lead ECGs from more than 30 device makers.
- Review, reporting and sign off, with HL7, FHIR and Epic integration.
- A marketplace that shows partners' cleared AI results in the review workflow, starting with a model for reduced ejection fraction.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and HeartSciences are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | HeartSciences |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2019 | 2007 |
| Headquarters | New York, New York, United States | Southlake, Texas |
| Website | accurkardia.com | heartsciences.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
AccurKardia makes AccurECG, cloud based software for automated interpretation of ambulatory ECG recordings, sold to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities.
Source: AI Health Index, September 2026
Healthcare information technology company (NASDAQ: HSCS). Its product is MyoVista Insights, a cloud ECG management platform on AWS that ingests resting 12-lead ECGs from more than 30 manufacturers' devices, supports review, reporting and sign off, and integrates with record systems through HL7 v2, FHIR R4 and SMART on FHIR, with Epic Toolbox designation for ECG management.
Source: AI Health Index, September 2026
Questions buyers ask
How are AccurKardia and HeartSciences priced and sold?
For AccurKardia, the company sells interpretation software to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities, and describes version 2.0 as built to process high volume ECG streams at lower cost; its site links terms of use.
With HeartSciences, the company cites Medicare reimbursement for assistive AI-ECG assessments under the Hospital Outpatient Prospective Payment System, APC 5734, at about $136 per assessment for 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do AccurKardia and HeartSciences handle patient data?
In AccurKardia's case, the data path crosses several organizations. The platform is cloud based and ingests recordings made on other companies' patches and Holter monitors, returning interpretations to monitoring services, hospitals and diagnostic testing facilities, so one recording can pass through a device maker, a monitoring service, this interpretation layer and a reading facility, each with its own terms.
For HeartSciences, the site describes HIPAA-compliant AWS infrastructure, a HIPAA-aligned audit trail and role based access on every record, and the annual report says the company expects to collect, process and retain patient information as a business associate. The only privacy policy published covers the website's contact and demo forms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do AccurKardia and HeartSciences cover?
With AccurKardia, the version 2.0 indication covers adults 22 and older prescribed outpatient cardiac monitoring for up to ten days, single lead recordings from wet silver chloride electrodes, assessed by qualified healthcare professionals in office or clinical settings, across 13 rhythm classifications, which is narrow and supported by FDA review.
In HeartSciences' case, the deployments named so far sit at the small end: a rural community hospital in Minnesota through the Cibolo network and a university ECG education center in England, with early adopter sites unnamed. The AI function has narrower coverage than the platform: one third party model for reduced ejection fraction in adults, validated by its developer under its own clearance. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price. HeartSciences' own AI algorithms are in development and not yet sold.
Ask AccurKardia how its interpretation performs on recordings from each device you use, and ask HeartSciences which AI models will be available in the marketplace and who is responsible for their results.